抗炎症：疫学考察 (～2030年)

当レポートでは、米国、欧州5ヶ国（ドイツ、スペイン、イタリア、フランス、英国）、および日本の7つの主要市場における抗炎症市場について詳細に説明し、疾患の背景と概要、アンメットニーズ、各国における疫学、治療法などに関する情報を提供しています。

目次

第1章 主な考察

第2章 エグゼクティブサマリー

第3章 抗炎症：疾患の背景と概要

• イントロダクション
• 兆候と症状
• 病態生理学
• 危険因子
• 診断

第4章 ペイシェントジャーニー

第5章 疫学と患者人口

• 疫学の主な調査結果
• 前提条件と理論的根拠：主要7ヶ国
• 疫学シナリオ：主要7ヶ国
  • 主要7ヶ国における抗炎症の疫学シナリオ
• 米国の疫学
  • 米国における抗炎症の疫学シナリオ
• 欧州5ヶ国の疫学：国別
  • ドイツの疫学
  • フランスの疫学
  • イタリアの疫学
  • スペインの疫学
  • 英国の疫学
• 日本の疫学
  • 日本における抗炎症の疫学シナリオ

第6章 治療アルゴリズム、現在の治療、および医療行為

• 抗炎症の治療と管理
• 抗炎症の治療アルゴリズム

第7章 KOL の見解

第8章 アンメットニーズ

第9章 付録

• 参考文献
• レポートの調査手法

第10章 DelveInsightのサービス内容

第11章 免責事項

第12章 DelveInsightについて

List of Tables

• Table 1: Anti-inflammatory Epidemiology in 7MM (2017-2030)
• Table 2: Anti-inflammatory Diagnosed and Treatable Cases in 7MM (2017-2030)
• Table 3: Anti-inflammatory Epidemiology in the United States (2017-2030)
• Table 4: Anti-inflammatory Diagnosed and Treatable Cases in the United States (2017-2030)
• Table 5: Anti-inflammatory Epidemiology in Germany (2017-2030)
• Table 6: Anti-inflammatory Diagnosed and Treatable Cases in Germany (2017-2030)
• Table 7: Anti-inflammatory Epidemiology in France (2017-2030)
• Table 8: Anti-inflammatory Diagnosed and Treatable Cases in France (2017-2030)
• Table 9: Anti-inflammatory Epidemiology in Italy (2017-2030)
• Table 10: Anti-inflammatory Diagnosed and Treatable Cases in Italy (2017-2030)
• Table 11: Anti-inflammatory Epidemiology in Spain (2017-2030)
• Table 12: Anti-inflammatory Diagnosed and Treatable Cases in Spain (2017-2030)
• Table 13: Anti-inflammatory Epidemiology in the United Kingdom (2017-2030)
• Table 14: Anti-inflammatory Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
• Table 15: Anti-inflammatory Epidemiology in Japan (2017-2030)
• Table 16: Anti-inflammatory Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

• Figure 1: Anti-inflammatory Epidemiology in 7MM (2017-2030)
• Figure 2: Anti-inflammatory Diagnosed and Treatable Cases in 7MM (2017-2030)
• Figure 3: Anti-inflammatory Epidemiology in the United States (2017-2030)
• Figure 4: Anti-inflammatory Diagnosed and Treatable Cases in the United States (2017-2030)
• Figure 5: Anti-inflammatory Epidemiology in Germany (2017-2030)
• Figure 6: Anti-inflammatory Diagnosed and Treatable Cases in Germany (2017-2030)
• Figure 7: Anti-inflammatory Epidemiology in France (2017-2030)
• Figure 8: Anti-inflammatory Diagnosed and Treatable Cases in France (2017-2030)
• Figure 9: Anti-inflammatory Epidemiology in Italy (2017-2030)
• Figure 10: Anti-inflammatory Diagnosed and Treatable Cases in Italy (2017-2030)
• Figure 11: Anti-inflammatory Epidemiology in Spain (2017-2030)
• Figure 12: Anti-inflammatory Diagnosed and Treatable Cases in Spain (2017-2030)
• Figure 13: Anti-inflammatory Epidemiology in the United Kingdom (2017-2030)
• Figure 14: Anti-inflammatory Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
• Figure 15: Anti-inflammatory Epidemiology in Japan (2017-2030)
• Figure 16: Anti-inflammatory Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report

DelveInsight's 'Anti-inflammatory - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Anti-inflammatory epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017-2030

Anti-inflammatory Understanding

The DelveInsight Anti-inflammatory epidemiology report gives a thorough understanding of the Anti-inflammatory by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Anti-inflammatory in the US, Europe, and Japan. The report covers the detailed information of the Anti-inflammatory epidemiology scenario in seven major countries (US, EU5, and Japan).

Anti-inflammatory Epidemiology Perspective by DelveInsight

The Anti-inflammatory epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Anti-inflammatory epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Anti-inflammatory epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Anti-inflammatory Detailed Epidemiology Segmentation

The Anti-inflammatory epidemiology covered in the report provides historical as well as forecasted Anti-inflammatory epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Anti-inflammatory report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

• The Anti-inflammatory report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Anti-inflammatory Epidemiology Report and Model provide an overview of the risk factors and global trends of Anti-inflammatory in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Anti-inflammatory in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Anti-inflammatory
• The report provides the segmentation of the Anti-inflammatory epidemiology

Report Highlights:

• 11-Year Forecast of Anti-inflammatory epidemiology
• 7MM Coverage
• Total Cases of Anti-inflammatory
• Total Cases of Anti-inflammatory according to segmentation
• Diagnosed cases of Anti-inflammatory

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anti-inflammatory?
• What are the key findings pertaining to the Anti-inflammatory epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
• What would be the total number of patients of Anti-inflammatory across the 7MM during the forecast period (2017-2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
• What is the disease risk, burden and unmet needs of the Anti-inflammatory?
• What are the currently available treatments of Anti-inflammatory?

Reasons to buy:

• The Anti-inflammatory Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Anti-inflammatory market
• Quantify patient populations in the global Anti-inflammatory market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Anti-inflammatory therapeutics in each of the markets covered
• Understand the magnitude of Anti-inflammatory population by its epidemiology
• The Anti-inflammatory Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Anti-inflammatory

3. Anti-inflammatory : Disease Background and Overview

• 3.1. Introduction
• 3.2. Sign and Symptoms
• 3.3. Pathophysiology
• 3.4. Risk Factors
• 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

• 5.1. Epidemiology Key Findings
• 5.2. Assumptions and Rationale: 7MM
• 5.3. Epidemiology Scenario: 7MM
  • 5.3.1. Anti-inflammatory Epidemiology Scenario in the 7MM (2017- 2030)
• 5.4. United States Epidemiology
  • 5.4.1. Anti-inflammatory Epidemiology Scenario in the United States (2017- 2030)
• 5.5. EU-5 Country-wise Epidemiology
  • 5.5.1. Germany Epidemiology
    • 5.5.1.1. Anti-inflammatory Epidemiology Scenario in Germany (2017- 2030)
  • 5.5.2. France Epidemiology
    • 5.5.2.1. Anti-inflammatory Epidemiology Scenario in France (2017- 2030)
  • 5.5.3. Italy Epidemiology
    • 5.5.3.1. Anti-inflammatory Epidemiology Scenario in Italy (2017- 2030)
  • 5.5.4. Spain Epidemiology
    • 5.5.4.1. Anti-inflammatory Epidemiology Scenario in Spain (2017- 2030)
  • 5.5.5. United Kingdom Epidemiology
    • 5.5.5.1. Anti-inflammatory Epidemiology Scenario in the United Kingdom (2017-2030)
• 5.6. Japan Epidemiology
  • 5.6.1. Anti-inflammatory Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

• 6.1. Anti-inflammatory Treatment and Management
• 6.2. Anti-inflammatory Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

• 9.1. Bibliography
• 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report